Since the end of 2021 Angelika Lep­pert is Man­aging Dir­ector (CFO) of KUPANDO GmbH, a bio­phar­ma­ceut­ical com­pany devel­op­ing a dual TLR agon­ist that stim­u­lates innate immunity and thus offers a poten­tially dis­rupt­ive ther­apy for the treat­ment of can­cer and infec­tious dis­eases. After com­plet­ing her inter­na­tional stud­ies in busi­ness admin­is­tra­tion, she worked as a con­sult­ant at Roland Ber­ger. In 1999, she moved to Medi­Gene AG, where she led the pre­par­a­tion and imple­ment­a­tion of the IPO and accom­pan­ied M&A trans­ac­tions. From 2006, she worked as a con­sult­ant in the areas of cor­por­ate fin­ance, strategy mod­er­a­tion, organ­iz­a­tional devel­op­ment and com­mu­nic­a­tion in vari­ous indus­tries. Before com­plet­ing the suc­cess­ful Series A for KUPANDO together with the founder, Mrs. Lep­pert worked as a start-up coach at BioM Biotech Cluster Devel­op­ment GmbH and was respons­ible for the devel­op­ment and imple­ment­a­tion of pan-European accel­er­ator pro­grams, an investor net­work and pitch days, among other things.